Whitehawk 2025 Q1 Earnings Strong Net Income Surge of 499.2%

Whitehawk (WHWK) reported its fiscal 2025 Q1 earnings on May 08th, 2025. The company's total revenue increased by 33.5% to $7.14 million, and it achieved a remarkable turnaround with a net income of $73.02 million, representing a 499.2% positive swing from the previous year's net loss. Whitehawk's earnings per share (EPS) saw a favorable change to $1.84, reversing from a loss of $0.68 per share in the same quarter last year. The company's guidance remains optimistic, with expectations to bring all three of its ADC assets to IND by mid-2026.

Revenue
The total revenue of Whitehawk increased by 33.5% to $7.14 million in 2025 Q1, up from $5.35 million in 2024 Q1.

Earnings/Net Income
Whitehawk returned to profitability with EPS of $1.84 in 2025 Q1, reversing from a loss of $0.68 per share in 2024 Q1 (370.6% positive change). Meanwhile, the company achieved a remarkable turnaround with net income of $73.02 million in 2025 Q1, representing a 499.2% positive swing from the net loss of $-18.29 million in 2024 Q1. Notably, the EPS indicates a significant improvement in the company's financial health.

Price Action
The stock price of Whitehawk has edged down 1.20% during the latest trading day, has edged down 1.80% during the most recent full trading week, and has edged down 0.61% month-to-date.

Post-Earnings Price Action Review
The strategy of purchasing Whitehawk (WHWK) shares after a quarter-over-quarter revenue decline and holding them for 30 days demonstrated a 9.16% annual return, with 66.88% of months being positive over the past five years. The maximum drawdown was 23.55% from January 1, 2022, to September 30, 2022, requiring an 18-month recovery period. This indicates a volatile yet potentially rewarding strategy, suitable for risk-tolerant investors with a moderate investment horizon.

CEO Commentary
"By uniting novel approaches to tumor targeting with next wave technologies, our goal at Whitehawk Therapeutics is to efficiently deliver improved ADC therapies for patients with difficult-to-treat cancers," said Dave Lennon, President and CEO of Whitehawk Therapeutics. The company made meaningful progress in advancing its portfolio toward the clinic and is on track to bring all three assets to IND by mid-2026, with the first IND expected to be filed in Q4 2025. The targeted assets, PTK7, MUC16, and SEZ6, are anticipated to have broad clinical impact with less competition. The strategic focus remains on advancing with urgency and purpose.

Guidance
Whitehawk Therapeutics anticipates bringing all three ADC assets to IND by mid-2026, with the first IND filing expected in Q4 2025. The company projects cash and cash equivalents of approximately $185 million post-transaction-related payments, which is expected to fund operations into 2028 based on current plans. The outlook includes expectations around the beneficial characteristics and market potential of its ADC assets, although actual results may differ due to various risks associated with clinical development and financial estimates.

Additional News
Whitehawk Therapeutics recently completed a significant strategic transformation by successfully closing the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $102.4 million. This transaction, announced in December 2024, involved the transfer of the Aadi Bioscience name, trademarks, and the FYARRO® business. Additionally, Whitehawk secured $100 million in PIPE financing, which, alongside the proceeds from the divestiture, is expected to fund operations into 2028. The company also relaunched as an ADC-focused oncology therapeutics entity, marking a pivotal evolution in its strategic direction.